AIM ImmunoTech Reaches Deal with Japan’s National Institute of Infectious Diseases to Test Ampligen as a Potential Treatment for Coronavirus

On March 9 th we announced that Japan’s National Institute of Infectious Diseases will begin testing AIM’s flagship drug Ampligen as a potential treatment for the deadly new coronavirus (COVID-19).

Learn more here.

Hemispherx News 04

Need More Info?

Let’s Talk